All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% stage IIIa stage IIIb stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - (neo)adjuvant (NA), pembrolizumab based treatment vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias MFSdetailed results KEYNOTE 054 (all population), 2018 0.53 [0.37; 0.76]
0.53 [0.37 ; 0.76 ] KEYNOTE 054 (all population), 2018 1 0% 1,019 NA not evaluable RFS (extension)detailed results KEYNOTE 054 (all population), 2018 0.59 [0.49; 0.71]
KEYNOTE 054 (PDL1>1%), 2018 0.57 [0.43; 0.75]
0.58 [0.50 ; 0.68 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable RFS/DFSdetailed results KEYNOTE 054 (all population), 2018 0.57 [0.43; 0.75]
KEYNOTE 054 (PDL1>1%), 2018 0.54 [0.42; 0.69]
0.55 [0.46 ; 0.66 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable DMFSdetailed results KEYNOTE 054 (all population), 2018 0.60 [0.49; 0.73]
KEYNOTE 054 (PDL1>1%), 2018 0.60 [0.49; 0.73]
0.60 [0.52 ; 0.69 ] KEYNOTE 054 (all population), 2018, KEYNOTE 054 (PDL1>1%), 2018 2 0% 1,872 low not evaluable AE (any grade)detailed results KEYNOTE 054 (all population), 2018 1.51 [0.96; 2.38]
1.51 [0.96 ; 2.38 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable AE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 2.03 [1.52; 2.73]
2.03 [1.52 ; 2.73 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable TRAE (any grade)detailed results KEYNOTE 054 (all population), 2018 6.05 [4.24; 8.63]
6.05 [4.24 ; 8.63 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 12.66 [3.87; 41.39]
12.66 [3.87 ; 41.39 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
5.95 [0.30 ; 119.02 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 10.04 [1.28; 78.73]
10.04 [1.28 ; 78.73 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 9.95 [0.54; 182.62]
9.95 [0.54 ; 182.62 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.32 [0.29; 5.92]
1.32 [0.29 ; 5.92 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE 054 (all population), 2018 18.05 [1.04; 312.27]
18.05 [1.04 ; 312.27 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results KEYNOTE 054 (all population), 2018 5.01 [1.09; 22.98]
5.01 [1.09 ; 22.98 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 6.99 [0.86; 56.99]
6.99 [0.86 ; 56.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
5.95 [0.30 ; 119.02 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 3.96 [0.18; 87.96]
3.96 [0.18 ; 87.96 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.06; 15.81]
0.99 [0.06 ; 15.81 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
7.94 [0.42 ; 150.67 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results KEYNOTE 054 (all population), 2018 7.94 [0.42; 150.67]
7.94 [0.42 ; 150.67 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 5.95 [0.30; 119.02]
5.95 [0.30 ; 119.02 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results KEYNOTE 054 (all population), 2018 1.97 [0.07; 58.99]
1.97 [0.07 ; 58.99 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results KEYNOTE 054 (all population), 2018 0.99 [0.02; 49.80]
0.99 [0.02 ; 49.80 ] KEYNOTE 054 (all population), 2018 1 0% 1,011 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 03:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 284,70,235
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561